

INPLASY PROTOCOL

To cite: Tian et al. Efficacy and safety of Janus kinase inhibitors for Ulcerative colitis: A Systematic Review and Meta-Analysis. Inplasy protocol 2021120096. doi: 10.37766/inplasy2021.12.0096

Received: 22 December 2021

Published: 22 December 2021

Corresponding author:
Tian Zhao

2282536125@qq.com

Author Affiliation:
Qinghai University

Support: 2019-SF-L3.

Review Stage at time of this submission: Preliminary searches.

Conflicts of interest:
None declared.

Efficacy and safety of Janus kinase inhibitors for Ulcerative colitis: A Systematic Review and Meta-Analysis

Tian, W¹; Shi, Q²; Lu, F³.

Review question / Objective: Ulcerative colitis is one of the most common types of inflammatory bowel disease and has become a common disease of digestive system in China. JAK inhibitors have been widely studied in diseases including rheumatoid arthritis and Crohn's disease and may represent a promising and novel therapeutic option for the treatment of UC. **P:** Patients with ulcerative colitis **I:** Janus kinase inhibitor **C:** Placebo **O:** Effective rate, adverse event rate **S:** RCT.

Condition being studied: Ulcerative colitis is one of the most common types of inflammatory bowel disease and has become a common disease of digestive system in China. JAK inhibitors have been widely studied in diseases including rheumatoid arthritis and Crohn's disease and may represent a promising and novel therapeutic option for the treatment of UC.

INPLASY registration number: This protocol was registered with the International Platform of Registered Systematic Review and Meta-Analysis Protocols (INPLASY) on 22 December 2021 and was last updated on 22 December 2021 (registration number INPLASY2021120096).

INTRODUCTION

Review question / Objective: Ulcerative colitis is one of the most common types of inflammatory bowel disease and has become a common disease of digestive system in China. JAK inhibitors have been widely studied in diseases including rheumatoid arthritis and Crohn's disease and may represent a promising and novel

therapeutic option for the treatment of UC. **P:** Patients with ulcerative colitis **I:** Janus kinase inhibitor **C:** Placebo **O:** Effective rate, adverse event rate **S:** RCT.

Condition being studied: Ulcerative colitis is one of the most common types of inflammatory bowel disease and has become a common disease of digestive system in China. JAK inhibitors have been

widely studied in diseases including rheumatoid arthritis and Crohn's disease and may represent a promising and novel therapeutic option for the treatment of UC.

METHODS

Search strategy: ("Janus Kinase Inhibitors"[MeSH Terms] OR ("inhibitors janus kinase"[Title/Abstract] OR "kinase inhibitors janus"[Title/Abstract] OR "jak inhibitors"[Title/Abstract] OR "inhibitors jak"[Title/Abstract] OR "janus kinase inhibitor"[Title/Abstract] OR "inhibitor janus kinase"[Title/Abstract] OR ("kinase s" [All Fields] OR "phosphotransferases"[MeSH Terms] OR "phosphotransferases"[All Fields] OR "Kinase"[All Fields] OR "kinases"[All Fields]) AND "inhibitor janus"[Title/Abstract] OR "jak inhibitor"[Title/Abstract] OR "inhibitor jak"[Title/Abstract])) AND ("colitis, ulcerative"[MeSH Terms] OR ("idiopathic proctocolitis"[Title/Abstract] OR "ulcerative colitis"[Title/Abstract] OR "colitis gravis"[Title/Abstract] OR ("inflammatory bowel diseases"[MeSH Terms] OR ("inflammatory"[All Fields] AND "bowel"[All Fields] AND "diseases"[All Fields]) OR "inflammatory bowel diseases"[All Fields] OR ("inflammatory"[All Fields] AND "bowel"[All Fields] AND "disease"[All Fields]) OR "inflammatory bowel disease"[All Fields] AND "ulcerative colitis type"[Title/Abstract]))) AND ("randomized controlled trial"[Publication Type] OR "randomized"[Title/Abstract] OR "placebo"[Title/Abstract]).

Participant or population: Patients with ulcerative colitis.

Intervention: Janus kinase inhibitor.

Comparator: Placebo.

Study designs to be included: RCT.

Eligibility criteria: 1. Inclusion criteria: 1) the type of study must be a randomized controlled trial; 2) Participants must be over 18 years old; 3) The subjects were diagnosed as ulcerative colitis by colonoscopy and biopsy histology.2.

Exclusion criteria: 1) minimal sample size; 2) Other related treatments were performed before intervention; 3) No placebo control; 4) Data cannot be extracted from the article; 5) Basic type experiment.

Information sources: VIP, Wanfang, readingshow, pubmed, embase, cochrane, web of science, scopus, cnki.

Main outcome(s): Effective rate, adverse events.

Data management: Endnote.

Quality assessment / Risk of bias analysis: Cochrane tool.

Strategy of data synthesis: In case of heterogeneity, random effects were selected to merge the data; There was no heterogeneity, and fixed effects were selected to consolidate the data.

Subgroup analysis: The subgroup study was conducted according to the patient's age, economy, environment and other factors.

Sensitivity analysis: After deleting any one of the literatures, the time difference between the combined results of the other literatures and those not deleted is not large, which means that through sensitivity analysis.

Country(ies) involved: China.

Keywords: Janus kinase inhibitor, ulcerative colitis.

Contributions of each author:

Author 1 - Tian Zhao.

Email: 2282536125@qq.com

Author 2 - Shi Qin.

Email: 1755832492@qq.com

Author 3 - Lu Fu.